EP0116538A1 - Methode et medicament de traitement du prurit - Google Patents

Methode et medicament de traitement du prurit

Info

Publication number
EP0116538A1
EP0116538A1 EP82902866A EP82902866A EP0116538A1 EP 0116538 A1 EP0116538 A1 EP 0116538A1 EP 82902866 A EP82902866 A EP 82902866A EP 82902866 A EP82902866 A EP 82902866A EP 0116538 A1 EP0116538 A1 EP 0116538A1
Authority
EP
European Patent Office
Prior art keywords
naloxone
pharmaceutically acceptable
acceptable salt
naltrexone
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP82902866A
Other languages
German (de)
English (en)
Other versions
EP0116538A4 (fr
Inventor
Joel E. Bernstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0116538A1 publication Critical patent/EP0116538A1/fr
Publication of EP0116538A4 publication Critical patent/EP0116538A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Definitions

  • the present invention relates to a composition for relieving pruritis.
  • pruritis Itching or pruritis is a common dermatologi ⁇ symptom. ⁇ p ne causes of pruritis are complex and poorly understood. The best understood mechanism of itching is the release of histamine in the skin leading to urticarial wheals-and intense itching. Such itching has traditionally been relieved by antihistamines. While antihistamine therapy is often effective, the sedation and drowsiness produced by antihistaminic agents limits their effectiveness.
  • Naloxone is a narcotic antagonist which is not known to cause physical or psychological dependence and which exhibits essentially no pharmacological activity in non-addicts. Naloxone is normally given by injection to addicts to assist them in narcotic with ⁇ drawal and"sometimes is administered to post operative patients for partial reversal of narcotic depression following the use of narcotics during surgery. It has been found surprisingly that topical " applications of Naloxone are useful in alleviating severe itching in various conditions.
  • the present invention provides a method for relieving severe itching in patients in need of such treatment, said method comprising topically administer ⁇ ing a therapeutically effective amount of Naloxone or a pharmaceutically acceptable salt thereof or Naltrex- one to a patient in need of such treatment.
  • Naloxone hydrochloride is commercially avail- able from Endo Laboratories, Inc., a subsidiary of the DuPont Company, 1000 Stewart Avenue, Garden City, New York 11530.
  • the preparation of Naloxone is disclosed in U.S. Patent No. 3,254,088.
  • pharmaceutically acceptable salts refers to the physiologically acceptable acid addition salts of Naloxone such as the hydrochloride, hydrobromide, hydroiodide, acetate, valerate, oleate, etc.
  • Liquid dosage forms for topical administra- tion includes acceptable emulsions, solutions and sus ⁇ pensions containing volatile diluents commonly used in the art, such as alcohol, glycol and the like. Besides such diluents, topically applied compositions may also include wetting agents, emulsifying and suspending agents.
  • & JREA the form of a pharmaceutically acceptable salt such as the hydrochloride and pharmaceutically acceptable chemical derivatives thereof such as Naltrexone which is the n-methyl cyclopropyl derivative are incorporated into solutions, lotions, creams, and ointments for topical application in concentrations of from 0.01 to about 5 percent by weight. These topical products are applied to the skin 1 to 8 times daily. The relief experienced by those receiving the topical application was prompt although temporary.
  • Naloxone hydrochloride 1 percent by weight Naloxone hydrochloride was incorporated into a solution composed of 70 percent by volume ethyl alcohol and 30 percent by volume propylene glycol and applied 6 times daily to 2 mosquito bites of less than 24 hours duration on an 11 year-old male. This child noted relief from his itching within 10 minutes of each application and the relief lasted 2-4 hours.
  • Eucerin (R.T.M) cream is a synthetic lanolin containing cream produced by Beiersdorf, Inc. of South Norwalk, Conneticut 06854. This was the first topical product the patient used that provided him with any significant relief from his itching.
  • Naloxone hydrochloride 5% by weight Naloxone hydrochloride was in ⁇ corporated into an ointment and applied 4 times daily for two days to a small eczematous patch on the left hand of a 38 hear-old male. Itching was dramatically reduced by each application of the test ointment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Traitement topique pour soigner le prurit suivant lequel de la Naloxone, un sel pharmaceutiquement acceptable d'un dérivé chimique pharmaceutiquement acceptable, est utilisée topiquement dans une lotion, une solution, une crème ou une pommade.
EP19820902866 1982-08-25 1982-08-25 Methode et medicament de traitement du prurit. Withdrawn EP0116538A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1982/001152 WO1984000889A1 (fr) 1982-08-25 1982-08-25 Methode et medicament de traitement du prurit

Publications (2)

Publication Number Publication Date
EP0116538A1 true EP0116538A1 (fr) 1984-08-29
EP0116538A4 EP0116538A4 (fr) 1985-04-25

Family

ID=22168155

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19820902866 Withdrawn EP0116538A4 (fr) 1982-08-25 1982-08-25 Methode et medicament de traitement du prurit.

Country Status (5)

Country Link
EP (1) EP0116538A4 (fr)
JP (1) JPS59501712A (fr)
AU (1) AU8952282A (fr)
DK (1) DK206584D0 (fr)
WO (1) WO1984000889A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201675B (en) * 1983-08-26 1990-12-28 Ivan Balkanyi Process for producing oral pharmaceutical compositions with unappetizing effect
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
GB9725114D0 (en) * 1997-11-28 1998-01-28 Pfizer Ltd Treatment of pruritus
DE602005011113D1 (de) * 2004-03-30 2009-01-02 Toray Industries Morphinanderivate als mittel gegen juckreiz
CN101426481B (zh) * 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
US20090093509A1 (en) * 2007-10-08 2009-04-09 Tahir Nazir Methods and Compositions for the Treatment of Pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
AU2019309913A1 (en) 2018-07-23 2021-03-11 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US4181726A (en) * 1978-11-16 1980-01-01 Bernstein Joel E Method of alleviating pruritis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No relevant documents have been disclosed. *
See also references of WO8400889A1 *

Also Published As

Publication number Publication date
JPS59501712A (ja) 1984-10-11
WO1984000889A1 (fr) 1984-03-15
AU8952282A (en) 1984-03-29
DK206584A (da) 1984-04-25
EP0116538A4 (fr) 1985-04-25
DK206584D0 (da) 1984-04-25

Similar Documents

Publication Publication Date Title
US4416886A (en) Method of treating pruritis and composition therefor
DE69737592T2 (de) Mittel gegen juckreiz
CA1254582A (fr) DERIVES DE PHENYL-.alpha.-ACYLOXYACETAMIDE ET LEUR UTILISATION COMME AGENTS THERAPEUTIQUES
DK159757B (da) Anvendelse af naphthalenderivater til fremstilling af et medikament til behandling eller profylakse af inflammation ved topisk administration og farmaceutisk praeparat til topisk anvendelse indeholdende naphthalenderivaterne
JP5613417B2 (ja) モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬
JPS6241688B2 (fr)
Paterson et al. Drug therapy of glaucoma.
US5426120A (en) Pharmaceutical composition containing γ-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
EP0116538A1 (fr) Methode et medicament de traitement du prurit
US5187177A (en) Method and a pharmaceutical preparation for treating pain
EP0541192A1 (fr) Utilisation d'antagonistes d'opiates pour le traitement de l'hyperinsulinémie endogène
CA1177406A (fr) Compose pour le traitement du prurit
US4181726A (en) Method of alleviating pruritis
US4946848A (en) Method of treating pruritus with nalmefene and clonidine
US4315024A (en) Compositions and method for treating red eye
March et al. Adrenal function after topical steroid therapy
CA1189794A (fr) Compose pour le traitement du prurit
US4829068A (en) Treatment of disorders of the gastro-intestinal tract
DE60024408T2 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE69113921T2 (de) Verwendung eines reinen Opiatantagonisten, z.B. Nalmefen, Naltrexon, Naloxon oder Diprenorphin, zur Behandlung von Mastzell-Erkrankungen.
O'LEARY et al. Benadryl in the treatment of certain diseases of the skin
US20140121240A1 (en) Novel pharmaceutical composition
RU2063753C1 (ru) Способ лечения экстрапирамидного синдрома при остром отравлении галоперидолом
DE69637416T2 (de) Topische anwendung von opioiden, wie morphin, zur linderung von juckreiz und hautkrankheiten sowie hautreizungen
US6693100B1 (en) Pharmaceutical compositions for treating psoriasis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB LI LU NL SE

17P Request for examination filed

Effective date: 19840914

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

17Q First examination report despatched

Effective date: 19860624

18D Application deemed to be withdrawn

Effective date: 19860304

D17Q First examination report despatched (deleted)